NuVasive logo
NuVasive NUVA
report update icon

Quarterly report 2023-Q2
added 08-02-2023

NuVasive Cash Flow 2022-2011 | NUVA

Brief cash flow overview of NuVasive

The review uses the five latest available annual reports between 2018 and 2022.

Across five available reports, cash from operations decreased from $219.2 million to $169.1 million, leaving a weaker cash base.

Each of the five years produced positive cash from operations, indicating stable cash generation.

Only 14.1% of revenue now converts into operating cash flow versus 19.9% previously.

Working capital needs increased $106.7 million, or 8.9% of sales. This may restrain cash conversion.

Overall picture

There is no unconditional cash flow signal for NuVasive. Repeatability of OCF and the quality of its use remain important.

Annual Cash Flow NuVasive

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

169 M 182 M 186 M 235 M 219 M 177 M 158 M - - 97.4 M 130 M 63 M

Depreciation & Amortization

147 M 150 M 141 M 136 M 130 M 121 M 103 M 65.9 M 65.8 M 63.1 M 51.9 M 36.2 M

Accounts Payables

20.3 M 16.2 M 17.4 M 11.8 M 8.8 M 4.37 M 9.12 M 6.79 M 13.6 M 14.3 M 9.04 M 11.3 M

Accounts Receivables

249 M 214 M 207 M 212 M 196 M 199 M 172 M 128 M 119 M 105 M 89 M 88.4 M

Total Inventories

339 M 316 M 301 M 312 M 273 M 247 M 208 M 168 M 155 M 137 M 126 M 119 M

All numbers in USD currency

Quarterly Cash Flow NuVasive

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- 1.97 M - 122 M - 6.54 M - 145 M - 31.6 M - 113 M 33.1 M 5.22 M - 161 M 93.4 M 24.5 M - 150 M 77.2 M 36.4 M - 119 M 67.1 M - - - - - - - - - - - - 23.3 M - 70.1 M 32.4 M 24.1 M - 99.5 M 65.8 M 39.7 M - 53.4 M 27.7 M 14.5 M

Depreciation & Amortization

8 M 33.5 M - 110 M 13.4 M 36.8 M - 112 M 15.9 M 36.4 M - 106 M 70.1 M 35 M - 101 M 67.6 M 34.1 M - 96.4 M 64.2 M 32.1 M - 88.9 M 58.7 M 29.5 M - 73.8 M 46.3 M 21.2 M - 49 M 32.6 M 16.1 M - 46.5 M 31 M 15.4 M - 46.3 M 30.3 M 14.6 M - 38.2 M 25.3 M 12.1 M - 24.8 M 15.9 M 7.78 M

Accounts Payables

- - - - - - 16.2 M - - - 17.4 M - - - 11.8 M - - - 8.8 M - - - 4.37 M - - - 9.12 M - - - 6.79 M - - - 13.6 M - - - 14.3 M - - - 9.04 M - - - 11.3 M - - -

Accounts Receivables

267 M 250 M 249 M 236 M - 231 M 214 M 199 M 217 M 205 M 207 M 207 M 207 M 207 M 212 M 212 M 212 M 212 M 196 M 196 M 196 M 196 M 200 M 200 M 200 M 200 M 172 M 172 M 172 M 172 M 128 M 128 M 128 M 128 M 119 M 119 M 119 M 119 M 105 M 105 M 105 M 105 M 89 M 89 M 89 M 89 M 87.7 M 87.7 M 87.7 M 88.4 M

Total Inventories

351 M 346 M 339 M 341 M - 324 M 316 M 311 M 320 M 316 M 301 M 301 M 301 M 301 M 312 M 312 M 312 M 312 M 273 M 273 M 273 M 273 M 247 M 247 M 247 M 247 M 208 M 208 M 208 M 208 M 168 M 168 M 168 M 168 M 155 M 155 M 155 M 155 M 137 M 137 M 137 M 137 M 126 M 126 M 126 M 126 M 119 M 119 M 119 M 119 M

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company NuVasive, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Medical devices sector

Issuer Price % 24h Market Cap Country
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Myomo Myomo
MYO
$ 0.93 -3.11 % $ 38.9 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 7.24 -0.14 % $ 219 M canadaCanada
AxoGen AxoGen
AXGN
$ 41.37 0.53 % $ 1.91 B usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.38 -3.15 % $ 144 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 4.44 -3.69 % $ 124 M australiaAustralia
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 61.74 -1.86 % $ 9.37 B usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 32.66 0.31 % $ 28.3 B britainBritain
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 27.4 -1.23 % $ 627 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 18.59 4.67 % $ 1.26 B usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.14 -2.68 % $ 400 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.86 -1.95 % $ 14.6 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 11.65 -2.27 % $ 453 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 10.95 -1.62 % $ 453 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.35 -4.32 % $ 21.8 M usaUSA
LENSAR LENSAR
LNSR
$ 5.25 -1.87 % $ 62.8 M usaUSA
Beyond Air Beyond Air
XAIR
$ 5.51 0.92 % $ 45.7 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.43 0.14 % $ 60 M usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 97.15 1.46 % $ 19.2 B usaUSA